Combined CTLA-4 and PD-1 blockade has been associated with more antitumor responses, one possible rationale being ipilimumab therapy increases tumor-infiltrating T cells and upregulates PD-1/PD-L1 inhibitory pathway in a compensatory fashion indicating that combination therapy may be more efficient [77,78]. This evidence concerns the gene CTLA4 and neoplasm.